Merck & Co., Inc. (MRK)
Merck signs deal with Jiangsu Hengrui worth up to $2 billion for access to heart drug
Merck has signed a deal with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion, the companies said on Tuesday, giving the U.S. drugmaker access to an experimental heart disease drug.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
In the closing of the recent trading day, Merck (MRK) stood at $94.02, denoting a -0.74% change from the preceding trading day.
Merck Loses Almost $52B in 6 Months: How to Play MRK Stock
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.
Merck (MRK) Advances While Market Declines: Some Information for Investors
In the closing of the recent trading day, Merck (MRK) stood at $94.71, denoting a +1.46% change from the preceding trading day.
Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Merck prevails in Gardasil safety litigation
A federal judge has ruled in favor of Merck in litigation accusing the drugmaker of concealing the risks of Gardasin, a vaccine to prevent cervical and other fatal cancers.
Merck opens vaccine manufacturing facility in North Carolina
Merck said on Tuesday it has opened a new $1 billion, 225,000-square-foot facility dedicated to vaccine manufacturing at its Durham, North Carolina, site.
Merck (MRK) Ascends While Market Falls: Some Facts to Note
Merck (MRK) closed at $94 in the latest trading session, marking a +0.87% move from the prior day.
Merck (MRK) Up 3.9% Since Last Earnings Report: Can It Continue?
Merck (MRK) reported earnings 30 days ago. What's next for the stock?
New version of Merck's cancer drug faces patent battle, WSJ reports
Merck has asked the U.S. patent office to reconsider patents that could prevent it from selling a new version of its cancer drug Keytruda, the Wall Street Journal reported on Wednesday.
Merck & Co., Inc. (MRK) Presents at TD Cowen 45th Annual Health Care Conference (Transcript)
Start Time: 14:30 January 1, 0000 3:05 PM ET Merck & Co., Inc.
These S&P 500 Stocks Have Low P/E Ratios — Time to Buy?
Purchasing stocks at the right time can maximize your return on investment, especially if you plan to buy and hold shares toward a short-term or medium-term financial goal. A stock's P/E ratio can give you an immediate idea of whether a stock is trading at, below or above fair value.
